Why the study?
Does chronic treatment with efonidipine or lisinopril alter renal arteriolar diameters in spontaneously hypertensive rats?
Does chronic treatment with efonidipine or lisinopril alter renal arteriolar diameters in spontaneously hypertensive rats?
Chronic treatment with efonidipine or lisinopril structurally enlarges efferent arteriolar diameters in hypertensive rats, which may contribute to their renoprotective effects.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications; extends preclinical data on renal arteriolar effects in hypertension models.
Efonidipine, a calcium antagonist, has been reported to dilate not only afferent but also efferent arterioles, thereby reducing glomerular hydrostatic pressure. We investigated the effect of chronic treatment with efonidipine or lisinopril on the afferent and efferent arteriolar diameters by the vascular cast technique. Four-week-old spontaneously hypertensive rats (SHR) were divided into three groups: untreated, efonidipine (25 mg/kg/day)-treated, and lisinopril (3 mg/kg/day)-treated. At 22 weeks of age, the renal vasculatures were fixed at the maximally dilated condition. The morphometrical measurements showed that the treatments with efonidipine and lisinopril caused structural alteration of the vasculature, resulting in significantly greater efferent arteriolar diameters than in untreated SHR. In addition, lisinopril-treated rats had wider afferent lumina. The renoprotective effect of efonidipine and lisinopril might be partly due to the structurally larger efferent arteriolar lumen.
No takes yet. Share an insight, caveat, or question.
Nakamura et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: